Funding clinical stem cell research
Steven Myint,
Senior fellow, Consultant, Adjunct Professor ,
A*star, ETPL, Duke-NUS
Funding clinical research is generally more costly than basic research. If research in this arena is to continue to thrive outside the multinational pharmaceutical communities then governments and the investment community needs to address the situation with larger grants and a better infrastructure. This talk gives a brief overview of the current situation, some novel approaches and the gaps that still need to be addressed.
|
|
